Breaking News, Collaborations & Alliances

HTG, Sanofi US in Companion Diagnostic Pact

Aims to identify biomarkers for Sanofi compound

HTG Molecular Diagnostics has established a collaborative agreement with Sanofi US to identify biomarkers for the development of a molecular companion diagnostic test for a novel Sanofi investigational compound. HTG’s qNPA technology measures mRNA and/or miRNA expression in tumor samples, allowing clinicians to identify certain biomarkers relevant to patient selection and therapy.

“We are pleased to be a partner with Sanofi in answering the need for personalized cancer treatments. qNPA offers options in diagnostics testing of FFPE tissues not available in other commercial technologies,” said TJ Johnson, chief executive officer of HTG Molecular Diagnostics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters